A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV
A phase 3 trial of Ropeginterferon alfa-2b in myeloproliferative neoplasms, run by PharmaEssentia, active and no longer recruiting.
Overview
A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV is a phase 3 interventional study registered as NCT05481151 by PharmaEssentia, with 111 participants enrolled, started 2022-10-26 and due to reach its primary completion in 2025-06-30. Interventions recorded: P1101 (Ropeginterferon alfa-2b-njft) and Ropeginterferon alfa-2b-njft (P1101).
Similar pages
not linked directly; found by shared links- TrialA Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET
Shares PharmaEssentia, Ropeginterferon alfa-2b, Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
- TrialA Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant or Resistance to HU
Shares PharmaEssentia, Ropeginterferon alfa-2b, Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
- TrialRopeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance
Shares PharmaEssentia, Ropeginterferon alfa-2b, Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
- TrialExtension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients
Shares Ropeginterferon alfa-2b, Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
- TrialP1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk
Shares PharmaEssentia, Ropeginterferon alfa-2b, Myeloproliferative neoplasms (PV, ET, myelofibrosis).
- TrialStudy to Assess SLN124 in Patients With Polycythemia Vera
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
- TrialA Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
- TrialStudy of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.